In January 2026, Hong Kong pharmaceutical companies launched intensive acquisition and authorization transactions!

【Pharmaceutical Network Industry Trends】Recently, WuXi AppTec announced its intention to acquire Dongyao Pharmaceutical through a tender offer at a premium of approximately 99%. The tender offer price is HKD 4 per share, and the total cost will reach HKD 2.79 billion. It is reported that WuXi AppTec and Dongyao Pharmaceutical are both pharmaceutical outsourcing enterprises, mainly engaged in the OEM of antibody conjugated drugs (ADCs).
 

This acquisition aims to directly transform Dongyao Pharmaceutical's existing production facilities, compliance qualifications, and mature production capacity into its available resources; Strengthen overall production capacity, while enriching project portfolio and expanding customer base. It is worth mentioning that WuXi AppTec will continue to actively and prudently promote its capacity expansion strategy in the future. From 2026 to 2029, it plans to invest over 7 billion yuan in the expansion of coupling, formulation, and load connection facilities both domestically and internationally.
 

Prior to this, on January 13th, China Biopharmaceutical also announced that it would fully acquire domestic siRNA innovative pharmaceutical company Hejiya Biotechnology for RMB 1.2 billion. This strategic acquisition aims to accelerate the group's innovative layout and clinical promotion in the field of chronic diseases, benefiting patients worldwide.
 

It is understood that Hegia has 4 clinical stage assets and more than 10 preclinical assets, all of which have first in class and best in class potential. Chinese biopharmaceuticals have already made rich layouts in the fields of chronic diseases such as respiratory diseases, liver diseases, and autoimmune diseases. By acquiring Hegia, it will help Guobiopharmaceutical complete the innovative drug layout of the next generation basic pipeline in the field of cardiovascular and cerebrovascular diseases, and significantly expand its territory in the areas of weight loss metabolism, neurological and psychiatric diseases. At the same time, it will accelerate the clinical promotion of its core pipeline and international market cooperation, fully unleashing its potential global value.
 

The above merger and acquisition transactions reflect the trend of industry resources being concentrated in hard technology and commercialization capabilities. It is worth noting that, in addition to mergers and acquisitions, several Hong Kong listed pharmaceutical companies have authorized overseas equity of their core assets to multinational pharmaceutical companies since 2026, obtaining huge down payments and research and development funds, and achieving resource integration and value realization.
 

On January 12th, Rongchang Biotechnology authorized the overseas rights of tumor dual antibody RC148 to AbbVie, with a down payment of 650 million US dollars. On the same day, Zhongsheng Peptide and Novartis reached a global exclusive authorization and cooperation agreement for a self-developed peptide asset, receiving a down payment of 50 million US dollars.
 

Analysts believe that the intensive acquisition and authorization transactions initiated by Hong Kong pharmaceutical companies in January 2026 are mainly driven by the compression of research and development cycles, the bottleneck of commercial production capacity, and the acceleration of global layout. This reflects that Chinese pharmaceutical companies are currently actively responding to the structural changes in the global pharmaceutical market by efficiently integrating resources, quickly filling the gaps in technology, production capacity, and globalization; And the clear trend of China's pharmaceutical industry transforming towards "hard technology+globalization+industry integration".
 

In the future, top enterprises with "hard technology+globalization+industry integration capabilities" are expected to dominate industry development and be favored by more capital; Enterprises with insufficient technology, funding, and commercialization capabilities will accelerate their clearance, and the industry will enter a new stage of high-quality development.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone.